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Available online 24 February 2011This study employed a targeted high-throughput proteomic approach to identify the major
proteins present in the secretome of articular cartilage. Explants from equine
metacarpophalangeal joints were incubated alone or with interleukin-1beta (IL-1β, 10 ng/ml),
with or without carprofen, a non-steroidal anti-inflammatory drug, for six days. After tryptic
digestion of culture medium supernatants, resulting peptides were separated by HPLC and
detected in a Bruker amaZon ion trap instrument. The fivemost abundant peptides in eachMS
scan were fragmented and the fragmentation patterns compared tomammalian entries in the
Swiss-Prot database, using the Mascot search engine. Tryptic peptides originating from
aggrecan core protein, cartilage oligomeric matrix protein (COMP), fibronectin, fibromodulin,
thrombospondin-1 (TSP-1), clusterin (CLU), cartilage intermediate layer protein-1 (CILP-1),
chondroadherin (CHAD) and matrix metalloproteinases MMP-1 and MMP-3 were detected.
Quantitativewestern blotting confirmed the presence of CILP-1, CLU,MMP-1,MMP-3 and TSP-1.
Treatmentwith IL-1β increasedMMP-1,MMP-3 and TSP-1 and decreased the CLU precursor but
did not affect CILP-1 and CLU levels. Many of the proteins identified have well-established
extracellular matrix functions and are involved in early repair/stress responses in cartilage.
This high throughput approachmay be used to study the changes that occur in the early stages
of osteoarthritis.
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Secretome1. Introduction
Articular cartilage is a mechanically resilient connective tissue
responsible for load-bearing and low-friction movement in the
synovial joints of all vertebrates [1]. The extracellular matrix
(ECM) of cartilage gives the tissue resilience and elasticity. The
ECM consists of three classes of molecules: collagens, aggre-
gating proteoglycans, and noncollagenous proteins. Type II, IX,; fax: +44 115 9516440.
m.ac.uk (A. Mobasheri).
er CC BY license.and XI collagens form a fibrillar framework of macromolecules
that give the tissue form, tensile stiffness and mechanical
strength [2,3]. Large aggregating proteoglycans (predominantly
aggrecan) allow cartilage to swell and resist compressive forces
[4,5]. Small proteoglycans including decorin, biglycan, and
fibromodulin, bind to other matrix macromolecules and help
to stabilise the ECM. Other collagenous and non-collagenous
macromolecules present within the ECM perform a variety of
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matrix interactions and bind growth factors [5,6]. The chon-
drocyte is the only cell type present in articular cartilage [7].
During embryonic development chondrocytes synthesise a
cartilaginous template for endochondral ossification and
skeletal development and in postnatal life they maintain the
ECM by regulating the turnover of matrix components in
response to biomechanical, biochemical and endocrine signals
[8]. Chondrocytes actively synthesise new ECM components as
well as the proteolytic enzymes responsible for catabolic
breakdown of cartilage. The matrix metalloproteinases
(MMPs), ADAMs (A Disintegrin And Metalloproteinase) and
ADAMTSs (A Disintegrin And Metalloproteinase with Throm-
bospondin Motifs) are the main proteolytic enzymes that
regulate ECM turnover in cartilage [9].
Osteoarthritis (OA) is a degenerative disease of synovial
joints that involves joint inflammation, bone remodelling and
destruction of the articular cartilage component [10,11]. In OA
there is an imbalance between the synthesis and degradation
of ECM macromolecules [12]. This can be due to increased
enzymatic activity of MMPs [13], and pro-inflammatory
mediators such as cytokines [14], prostaglandins and nitric
oxide [15], coupled with the reduced anabolic capacity of
chondrocytes [16] and the tissue's inherently poor reparative
capacity due to its avascular nature [7]. Consequently OA is
characterised by the loss of structural constituents from the
ECM. The degradation and release of proteins and glycopro-
teins from cartilage in OA can vary according to the stage of
the disease process. For example, elevated serum cartilage
oligomeric matrix protein (COMP) is correlated with the
presence of OA and disease severity [17]. Therefore, the ability
to detect biomarkers of cartilage degradation and/or inflam-
mation in biological samples, such as serum, urine or synovial
fluid,may enable clinicians to diagnose sub-clinical OA aswell
as determining the disease stage in both human and
companion animals. Identifying these biomarkers will also
aid drug discovery and drug safety/efficacy monitoring in
patients and in animal models. Using combinations of
biomarkers may be more effective in achieving these goals,
thus having a panel of biomarkers will help researchers and
the pharmaceutical industry to monitor disease progression
as well as to assess responses to treatment in experimental
models of OA [18,19].
Proteomics is being increasingly applied in basic cartilage
biology [20] and OA research [21]. Characterisation of cell
lysates from isolated chondrocytes has yielded valuable
information regarding the intracellular proteins of the chon-
drocyte proteome, and paved the way for future studies on
cartilage pathologies such as OA [22,23]. Studies of soluble
proteins in cartilage tissue from OA patients have increased
the knowledge of the proteins contained within the ECM of
diseased versus normal tissue [24]. A number of papers have
reported on proteins secreted from the cartilage ECM in
response to pathological insults such as interleukin (IL)-1α
and all-trans-retinoic acid [23,25,26], IL-1β and [27] and
mechanical compression [28–30]. Identifying proteins released
from cartilage explants has the potential to give an indication
of disease biomarkers likely to be present in the synovial fluid
or blood of patients in the early stages of OA. The cartilage
explant model also maintains and supports chondrocyteswithin their natural physicochemical microenvironment. This
in vitromodel is popular because it can overcome many of the
complicating variables associated with the de-differentiation
of chondrocytes inmonolayer culture aswell as the challenges
of interpreting data from animal models and in vivowork. The
horse is a suitable species from which cartilage is used to
model human OA, owing to the fact that horses are athletic
animals that can suffer from joint injuries similar to those in
human athletes. The equine cartilage explant model is well
established in our laboratory and has been used to develop in
vitro culturesmimicking joint inflammation using pro-inflam-
matory cytokines. For these reasons, the present study used
healthy equine cartilage explants cultured in serum-free
media, either alone (representing healthy cartilage), in the
presence of the pro-inflammatory cytokine equine IL-1β
(equine recombinant protein) to replicate the early inflamma-
tory stages of OA, or a combination of IL-1β and carprofen (a
COX-2 specific non-steroidal anti-inflammatory drug (NSAID)
commonly used to treat arthritic symptoms and joint inflam-
mation) to simulate anti-inflammatory pharmacotherapy. Our
aim was to use proteomic analysis of the explant culture
media to identify the major proteins secreted from cartilage.2. Materials and methods
2.1. Cartilage explant culture
Macroscopically normal articular cartilage was obtained from
the weight bearing regions of the metacarpophalangeal joints
of three horses. The animals used in this study were sourced
from the abattoir and were euthanized for purposes other
than research. The study received the full approval of the local
ethics committee but since abattoir tissues were used it was
exempt from review by animal welfare authorities. Articular
cartilage from individual animals was kept separate through-
out the study. Cartilage shavings of equal thickness were
aseptically harvested into low glucose (1 g/L glucose) Dulbec-
co's Modified Eagle's Medium (DMEM) (HyClone) containing
4% penicillin/streptomycin (Gibco) before being washed twice
in PBS for 20 min. Cartilage shavings from each animal were
cut into 3 mmdiscs using a sterile biopsy punch and five discs/
well were placed into 18 wells, containing 1 ml of DMEM
supplemented with 2% penicillin/streptomycin. Plates were
incubated overnight (37 °C/5% CO2). Media was then replaced
with fresh media.
2.2. Experimental design
Explants from three separate animals were subjected to three
different treatments; control, IL-1β and NSAID+IL-1β. Six
replicates per treatment for each of the 3 animals were used
totalling to 18 samples per animal, and altogether equalling to
54 samples in total. All wells contained 1 ml of the culture
medium. Control wells contained the culture media alone.
Recombinant equine IL-1β (10 ng/ml; R&D Systems)was added
to the remaining wells to induce cartilage inflammation. IL-1β
alone formed the negative control and the addition of a NSAID,
carprofen (100 μg/ml; Rimadyl®, Pfizer Animal Health), to the
remaining IL-1β-treated wells acted as a positive control to
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incubated at 37 °C and 5% CO2 for six days. The viability of the
chondrocytes in explants treated for six days with IL-1β- was
checked using a LIVE/DEAD® Cell Viability Assay (Invitrogen).
Cell viability was unaffected by exposure to IL-1β (10 ng/ml)
for this period of time (data not shown). After six days, the
supernatants were removed and split into two aliquots before
freezing at −20 °C. A schematic overview of the experimental
design is shown in Fig. 1.
2.3. Trypsin digestion of soluble proteins
Protein content of the samples was quantified using a
Detergent Compatible (DC) Protein Assay (Bio-Rad). Dithio-
threitol (DTT, Sigma-Aldrich) was added to 100 μl of each
sample to a final concentration of 10 mM and incubated at
37 °C for 30 min. Iodoacetamide (Sigma-Aldrich) (55 mM) was
added to each sample and incubated for 45 min at 37 °C in the
dark. Ice-cold acetone (Sigma-Aldrich) was added to each tube
and mixed well. Samples were incubated on ice for 1 h,
vortexing for 10 s every 15 min. The precipitate was then
centrifuged at 15,000×g for 5 min at 4 °C and the supernatant
was discarded. The pellet was air dried and re-suspended in
50 mM ammonium bicarbonate (Sigma-Aldrich) solution to a
final concentration of 10 μg/mL. Mass Spectrometry Grade
trypsin (Promega) was added to each tube at a ratio of 1:50
enzyme/target protein and incubated overnight at 37 °C. The
reaction was stopped by adding 1 μl of formic acid (Sigma-
Aldrich). Trypsin digested samples were stored at −80 °C until
analysis by ESI mass spectrometry.
2.4. Analysis by LC–MS/MS
Liquid chromatography was performed using an Easy-nLC
(Bruker UK Ltd) under the control of Hystar (Bruker UK Ltd).
Peptides generated by tryptic digestion were prepared for
LC–MS/MS as follows; 2 μl of digest was added to 48 μl ofFig. 1 – Schematic overview of the expesolvent A (95%(v/v) H2O, 5%(v/v) acetonitrile (Sigma-Aldrich),
and 0.1%(v/v) formic acid (Sigma-Aldrich)). A volume (5 μl) of
this dilution was then loaded onto a C18 Pepmap column
(75 μm ID, 15 cm, LC Packings). Peptides were separated at a
flow rate of 300 nl/min and the introduction of solvent B (95%
(v/v) acetonitrile, 5%(v/v) water, and 0.1%(v/v) formic acid) over
a 30 min linear gradient (solvent B went from 0% to 5% in 30 s,
then from 5% to 55% in 22 min, up to 95% in 4 min, was held at
95% for 2 min 30 s to wash the column, then returned to 5%
over 1 min followed by 10 min of equilibration in 5% before the
next injection, total run time 40 min). The LC system was
interfaced directly with a 3-D high capacity ion trap mass
spectrometer (amaZon, Bruker Daltonics) via the nanoESI
spray source and a target of 200,000 was set for SmartICC™.
Up to five precursor ions above a threshold of 10,000 were
selected per MS scan. Each precursor was fragmented twice
and then themasswas excluded for 1 min. Singly charged ions
were excluded. SPS tuningwas allowed for transmission of the
precursor into the trap. SmartFrag™ controlled the fragmen-
tation of each precursor ion and this was achieved using
helium gas and a 30–200% collision energy range with an
amplitude of 1.3 V.
2.5. Data processing and analysis
Raw LC–MS/MS data were processed automatically and
Mascot compatible files (*.mgf) created using DataAnalysisTM
4.0 software (Bruker UK Ltd) with the following parameters:
compounds (autoMS) threshold 10,000, number of compounds
was unlimited, retention time windows were 1 min for C18
(30 min gradient).
Database searches were performed using Mascot [31]
software and the Swiss-Prot database (version 51.6), with the
following parameters: 2+ and 3+ ions, peptide tolerance 0.5 Da,
13C=1, fragment tolerance 0.5 Da, missed cleavages: 1, and
instrument type: ESI-TRAP. Fixed modifications: carbamido-
methyl cysteine and variable modifications: oxidation ofrimental design used in this study.
Fig. 2 – Silver-stained 1-dimensional gel (1-D) protein profiles
of medium from cartilage explants incubated alone (control,
C), or treatedwith equine interleukin-1beta (β) (IL), or with a
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dues. Individual MS/MS spectra for peptides with a Mascot
Mowse score1 lower than 40 were inspected manually and
only included in the statistics if a series of at least four
continuous fragment ions were observed.
2.6. Submission of MS data to PRIDE
Fragmentation spectra, protein and peptide identifications
from further Mascot searches of the most recent SwissProt
database (UniProtKB Release 2011_01) are available in the
PRIDE database [32] (http://www.ebi.ac.uk/pride/) at the Euro-
pean Bioinformatics Institute under accession number 15852.
The data was converted using PRIDE Converter [33] (http://
code.google.com/p/pride-converter).
2.7. Western blot validation of selected proteins
Western blotting was used to confirm the presence of a
representative group of proteins identified by high throughput
proteomics. Replicate samples for each treatment were
combined to give a total of three samples per animal. The
protein content of each sample was quantified using a DC
Protein Assay (Bio-Rad) and concentrated by freeze-drying
(Heraeus-Christ) to yield 50 μg of total protein per sample.
Proteins extracted from equine cartilage shavings were used
as positive controls. The tissue was frozen in liquid nitrogen
and crushed into a fine powder in a pre-cooled mortar and
pestle. Supernatant and cartilage control samples were re-
suspended in NuPAGE® LDS sample buffer (Invitrogen), and
loaded onto 4–12% NuPAGE® buffered gradient pre-cast Bis/
Tris gels (50 μg protein/lane, Invitrogen). Samples were
electrophoresed for 1 h under reducing conditions at 200 V.
Gels were electro-transferred onto polyvinyl difluoride (PVDF,
Invitrogen) membranes for another hour at 30 V. After
blocking in Marvel/Tween (5% nonfat dry milk powder, 0.05%
Tween 20 in TBS), primary antibodies were diluted as
recommended by the manufacturer in Marvel/Tween and
added to the membrane for overnight incubation at 4 °C.
The specificity and cross-reactivity of each of the commer-
cial antibodies used in this study was validated by analysis of
the total proteins extracted from equine cartilage shavings.
CILP-1 blots were probed using a polyclonal sheep antibody
(1:300 dilution, R&D Systems). Clusterin (1:500 dilution, Santa
Cruz) and MMP-3 (1:1000 dilution, Abcam) blots were probed
with goat polyclonal antibodies. A rabbit polyclonal to MMP-1
(Abcam) was used at a dilution of 1:5000. TSP-1 (1:50 dilution,
Santa Cruz) and TSP (1:1000 dilution, Abcam) blots were
probed with mouse monoclonal antibodies. All the antibodies
selected for use in this study were produced against human
peptide sequences with 99–100% identity to their counterparts
in Equus caballus. The peptide sequences used by each
manufacturer for antibody production were checked using
the NCBI Basic Local Alignment Search Tool (Protein BLAST;
http://blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE=Proteins).
Appropriate secondary antibodies conjugated to horserad-
ish peroxidise (HRP) were used diluted in Marvel/Tween;1 Mowse scoring algorithm http://www.matrixscience.com/
help/scoring_help.html#MOW.polyclonal sheep HRP (diluted 1:10,000, Abcam), polyclonal
rabbit anti-goat immunoglobulins/HRP (diluted 1:10,000, Dako)
and anti-mouse/anti-rabbit labelled polymer HRP (diluted
1:400, Dako).
Chemiluminescence was used to detect the protein bands
using ECL+(GE Healthcare) on a Typhoon Trio+ Variable Mode
Imager (GE Healthcare). Densitometric quantification of the
western blot bands was performed using ImageJ software
(http://rsbweb.nih.gov/ij/; National Institutes of Health,
Bethesda, MD). The relative intensity of protein bands in IL-
1β and NSAID+IL-1β treated samples was compared to those
in control samples from each animal.3. Results
Silver staining of 1-D gels revealed differences in the
secretome protein profiles between control, IL-1β-treated
and IL-1β plus NSAID-treated samples (see Fig. 2). The
differences observed by 1-D PAGE and silver staining sug-
gested that there are alterations in the secretomes of
differently treated cartilage explants and catalysed the
subsequent phases of this work.
The majority of the secreted proteins identified using LC–
MS/MS with high Mowse scores in multiple samples were
cartilage ECM proteins or proteins with well-establishedmatrix
functions (see Table 1). Abundant proteins that were identified
in the majority of the samples from all animals included
aggrecan core protein, fibronectin, decorin and COMP. The
database search identified some proteins more frequently (in
terms of Mascot hits) in the IL-1β-treated samples compared to
the untreated controls, namely MMP-3 and TSP-1.
Cross species peptide matching [34,35] enabled the identi-
fication of proteins for which the equine versions were absent
or incomplete. Some peptides, such as decorin, matched
proteins from multiple species (human, horse, cow, rat, dog
and rabbit). Where the horse sequence was present in the
database, it generally achieved the top Mascot Mowse scorenon-steroidal anti-inflammatory drug plus IL combined (N).
Each set of 3 lanes labelled C, IL and N represent samples
from a different animal.
Table 1 – Secreted extracellular matrix proteins and proteolytic enzymes present inmultiple samples as identified using the
SwissProt 51.6 database.
Protein name Species matched Accession
number
SwissProt
entry name
Mascot
Mowse score
Sequence
coverage (%)
No. of matched
peptides
Fibronectin Mouse, cow, rat, horse P07589 FINC_BOVIN 642 9 16
Cartilage oligomeric matrix
protein
Human, mouse, cow, rat Q9R0G6 COMP_MOUSE 554 16 11
Matrix-metalloproteinase-3 Horse Q28397 MMP3_HORSE 366 19 11
Aggrecan core protein Human, mouse, rat, pig, dog P16112 PGCA_HUMAN 353 3 8
Clusterin Horse, dog Q29482 CLUS_HORSE 318 14 5
Thrombospondin-1 Human, mouse, cow P07996 TSP1_HUMAN 227 5 6
Matrix-metalloproteinase-1 Horse, cow Q9XSZ5 MMP1_HORSE 227 10 5
Fibronectin Mouse, cow, rat, horse Q28377 FINC_HORSE 221 11 3
Chondroadherin Human, mouse, cow, rat O15335 CHAD_HUMAN 220 13 4
Biglycan Horse, cow O46403 PGS1_HORSE 183 13 4
Decorin Human, horse, cow, rat, dog,
rabbit
O46542 PGS2_HORSE 156 10 3
Cartilage intermediate layer
protein−1
Human, mouse, pig O75339 CILP1_HUMAN 99 2 3
Prolargin precursor Human, mouse P51888 PRELP_HUMAN 96 3 1
TNF receptor 11B precursor Mouse O08712 TR11B_MOUSE 87 3 1
Fibromodulin Human, mouse, cow, rat,
horse
P50609 FMOD_RAT 82 8 3
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closest homologue. The only exceptionwas fibronectin, which
achieved a top Mascot Mowse score of 642 with the bovine
sequence but only 221 with the equine sequence. This is likely
to be due to the equine entry in the database being
considerably truncated.Where the horse sequencewas absent
from the database, multiple species matching increased
confidence in the protein detected, for example, aggrecan
core protein which had peptide matches with human, mouse,
rat, pig and dog. Some peptides only matched proteins from
one species such as equine MMP-3, or two species such as
equine and bovine MMP-1.
The majority of the proteins identified in this study were
ECM components or ECM-associated, however, a small
number of non-structural proteins were also found. Ten
non-ECM proteins were present in multiple samples and areTable 2 – Non-extracellularmatrix proteins identified in six orm
Protein name Species
matched
Accession
number
Vimentin Cow, green
monkey
P48616
Serum amyloid A protein Cow, horse P19857
Alpha Enolase Human, cow Q9XSJ4
Serum amyloid A2 protein American
mink
P02739
Transcription termination factor 1 Human Q15361
Serum albumin Cow P02769
Breast cancer type 2 protein susceptibility
homolog
Cat Q864S8
Lysozyme C, kidney isozyme Sheep P80190
Sodium/hydrogen exchanger 2 Rabbit P50482
Cytoplasmic dynein 1 heavy chain 1 Human Q14204shown in Table 2. Many of these had low Mowse scores under
55, except serum albumin precursor with a score of 71.
Many proteins were only identified in a single sample
from the 54 samples tested (18 samples per treatment).
Table 3 details peptides from these proteins that contained
four or more continuous fragment ions in a series. The
presence of four or more fragment ions in a row was defined
as the criterion for which a single peptide match was
considered to be a true positive, rather than five fragment
ions as is standard. Some of the peptides were small and only
consisted of five or six amino acids and the detection of all
the fragment ions is unlikely, therefore the detection of four
ions in a row was set as the confirmation limit. This enabled
the identification of four extra proteins; glucose-6-phosphate
1-dehydrogenase 2, centromere protein C1, lactadherin and
max-like protein X, as shown in Table 3. The presence ofore samples as identified using the SwissProt 51.6 database.
SwissProt
entry name
Mascot
Mowse score
Sequence
coverage (%)
No. of matched
peptides
VIME_BOVIN 301 12 6
SAA_HORSE 123 25 3
ENOA_BOVIN 94 7 4
SAA2_MUSVI 74 12 2
TTF1_HUMAN 68 2 3
ALBU_BOVIN 71 1 1
BRCA2_FELCA 51 0 3
LYSCK_SHEEP 47 6 1
SL9A2_RABBIT 45 1 1
DYHC1_HUMAN 44 0 1
Table 3 – Non-extracellular matrix proteins identified in only one sample. The identifications of these proteins relied on
peptides with four or more continuous fragment ion matches in a row using the SwissProt 51.6 database.
Protein name Species
matched
Accession
number
SwissProt
entry name
Mascot
Mowse
score
Sequence
coverage (%)
No. of
matched
peptides
No. of continuous
fragment ions
in a series
Keratin, type II cytoskeletal 1 Human P04264 K2C1_HUMAN 87 3 2 9
Triosephosphate isomerase Dog P54714 TPIS_CANFA 52 4 1 9
Fc receptor-like A Mouse Q920A9 FCRLA_MOUSE 49 1 1 5
Glucose-6-phosphate 1-dehydrogenase 2 Mouse P97324 G6PD2_MOUSE 45 3 2 4
Centromere protein C1 Mouse P49452 CENPC_MOUSE 42 0 1 4
Lactadherin Pig P79385 MFGM_PIG 40 2 1 4
Max-like protein X Human Q9UH92 MLX_HUMAN 38 2 1 4
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for example keratin from hair, skin or nails during tissue
collection, culture or sample processing [36]. Table 4 shows
the proteins found in only one sample, which have peptides
with fewer than four continuous fragment ions in a series.
These proteins have low Mowse scores of 55 or less.
The tables presented do not provide any quantitative
information about differences among control, IL-1β-treated
and IL-1β plus NSAID-treated samples with regard to theTable 4 – Non-extracellular matrix proteins identified in only o
peptides with fewer than 4 continuous fragment ion matches i
Protein name Species
matched
Accession
number
DNA-dependent protein kinase catalytic
subunit
Dog Q8WN22
Serine-protein kinase ATM Mouse Q62388
Histone acetyltransferase Human Q8WYB5
Bromodomain and PHD finger-containing
protein 3
Human Q9ULD4
Ubiquitin carboxyl-terminal hydrolase 24 Human Q9UPU5
Putative pre-mRNA-splicing factor ATP
dependent RNA helicase DXH15
Human O43143
Nuclear mitotic apparatus protein 1 Human Q14980
Bullous pemphigoid antigen 1 Human Q03001
Sodium/calcium exchanger 1 Cow P48765
Thyroid receptor-interacting protein-11 Human Q15643
Plectin-1 Rat P30427
Bcl-2/adenovirus E1B 19 kDa-interacting
protein 2-like protein
Mouse Q99JU7
Epidermal growth factor receptor kinase
substrate 8-like protein 3
Human Q8TE67
Glutaminyl-tRNA synthetase Human P47897
Integrin beta-5 Human P18084
Glial fibrillary acidic protein Cow Q28115
Phosphoglycerate kinase 1 Chinese
Hamster
P50310
Synergin gamma (AP1 subunit gamma-
binding protein 1)
Mouse Q5SV85
Beta, beta carotene 9′,10′-oxygenase Crab eating
macaque
Q8HXG8
Death-associated protein kinase 3 Rat O88764
Isocitrate dehydrogenase [NAD]
subunit beta, mitochondrial
Cow O77784
Cytosolic phospholipase A2 delta Mouse Q50L43
Protein arginine deiminase type-4 Human Q9UM07abundance of the proteins listed. The approach used only
determined the presence or absence of proteins. Therefore
quantitative western blotting was used to validate and quantify
a selected number of the proteins identified. This approach
confirmed the presence of selected matrix associated proteins
andhelped quantify the relative intensities of the protein bands
in the IL-1β-treated and IL-1β plus NSAID-treated samples
versus the untreated controls. Western blotting confirmed the
presence of CILP-1, CLU, MMP-1, MMP-3 and TSP-1 in thene sample. The identifications of these proteins relied on
n a row using the SwissProt 51.6 database.
SwissProt
entry name
Mascot
Mowse score
Sequence
coverage (%)
No. of matched
peptides
PRKDC_CANFA 55 0 3
ATM_MOUSE 55 0 3
MYST4_HUMAN 53 1 2
BRPF3_HUMAN 51 2 3
UBP24_HUMAN 50 0 2
DHX15_HUMAN 48 2 2
NUMA1_HUMAN 48 0 2
BPA1_HUMAN 47 0 2
NAC1_BOVIN 47 1 2
TRIPB_HUMAN 47 0 1
PLEC1_RAT 46 0 3
BNIPL_MOUSE 45 6 1
ES8L3_HUMAN 44 2 2
SYQ_HUMAN 44 2 2
ITB5_HUMAN 43 1 2
GFAP_BOVIN 43 5 2
PGK1_CRIGR 43 2 1
SYNRG_MOUSE 42 1 2
BCDO2_MACFA 42 3 2
DAPK3_RAT 41 2 1
IDH3B_BOVIN 41 1 1
PA24D_MOUSE 40 2 2
PADI4_HUMAN 39 1 2
Fig. 3 –Western blot images of explantmedium fromcartilage explants alone (control, C), and treatedwith equine interleukin-1beta
(β) (IL), or with IL-1β and a non-steroidal anti-inflammatory drug (N) combined. Blotting for cartilage intermediate layer protein-1
(CILP-1), clusterin (CLU), matrix metalloproteinase (MMP)-1 and MMP-3, thrombospondin (TSP)-1 and a pan antibody to 4 forms of
TSP. Arrows indicate observed molecular weights (MW) in kilo Daltons (kDa).
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protein levels of MMP-1, MMP-3 and TSP-1 in comparison to
controls and MMP-3 was actually present in lower amounts inthe NSAID-treated samples. The weak band(s) in the tissue
homogenate controls showed that MMP-3 was present in
cartilage, albeit at much lower concentrations.
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Proteomics is increasingly applied in basic and clinical
rheumatology and orthopaedics to help understand the
biology of joint tissues, responses to pro-inflammatory
cytokines and growth factors as well as mechanical signals
[23,27,29,30]. Proteomic techniques also have the potential to
identify novel biomarkers of joint diseases. In this study we
set out to refine a serum-free explant model of articular
cartilage inflammation and tested the feasibility of using it for
studying the major proteins present in the secretome. The
explant model was originally established in our laboratory
with the intention of using it as a screening system for testing
the effects of putative anti-inflammatory compounds from
plant extracts [37] as well as identifying biomarkers of early
OA. High throughput proteomics and cross species peptide
matching were then used to identify the main proteins
present in the secretome. This approach has a key advantage:
it does not require gel electrophoresis and is more rapid than
traditional 2-D gel MALDI-TOF MS analysis.
Using comparative proteomic analysis, we identified several
constitutively expressed ECMmolecules in the supernatants of
cartilage explants, namely aggrecan, fibromodulin, decorin,
biglycan and COMP. These proteins have been identified in
proteomic studies in human [24] andmouse [25] cartilage, thus
facilitating the validation of our equine cartilage model. One of
the most abundant proteins in the explant media was COMP, a
non-collagenous matrix protein that mediates chondrocyte
attachment to the ECM [38] and organises ECM assembly [39].
COMPhas been suggested as a potential biomarker for OAand it
has been detected in synovial fluid, serum and urine from
human and equine OA patients [17,40–44]. Moreover, its
presence correlates with disease severity and progression.
The presence of COMP in this model, concurs with that of
other in vitro studies that have found COMP abundant in media
exposed to cartilage explants [24,25,28].
Western blotting confirmed that IL-1β-treatment increases
the abundance of MMP-3 in the cartilage secretome. MMP-3 is
a proteolytic enzyme that degrades ECM components such as
fibronectin, collagens and cartilage proteoglycans. Its levels
are increased in clinical OA cases and the gene encoding
this protein has been shown to be up-regulated in IL-1β-
stimulated chondrocytes in vitro [45,46]. Immunohistochemi-
cal studies have reported MMP-3 in the synovium, cartilage
and medium of cultured cartilage explants from OA patients
[13]. Our qualitative LC–MS/MS data suggested that MMP-3
was higher in IL-1β-treated samples compared to controls and
this observation was confirmed by western blotting. NSAID-
treatment actually reduced MMP-3 levels, an observation that
has been found previously for bovine MMP-3 mRNA and
protein [47]. The weak band(s) in the tissue homogenate
controls showed that MMP-3 was present in cartilage, but in
lower concentrations than in the IL-1β-treated samples and
thus may have been below the detection threshold used to
analyse the samples.
Western blotting for MMP-1 detected a band of roughly
102 kDa in both the cartilage control and all the secretome
samples (present as a double band in IL-1β-treated samples
corresponding to active and inactive forms), which was nearlydouble the predicted molecular weight (54 kDa). Although the
samples were run under reducing conditions, it may be that
the observed band corresponds to a dimer form of MMP-1 that
was resistant to the reducing agent.
The equine sequence for TSP-1 was not present in the
Swiss-Prot database at the time of this study but cross species
matching with bovine, human and mouse confirmed the
presence of TSP-1. The fragments matched the protein motifs
of TSP-1 from multiple other species, thus increasing our
confidence in the detection of this protein in the horse
cartilage secretome. The presence of TSP-1was also confirmed
by western blotting using two different commercial antibo-
dies. TSP-1 is an adhesive glycoprotein that mediates cell-to-
cell and cell-to-matrix interactions [48,49]. Human cartilage
studies have shown that TSP-1 is increased in early OA
cartilage lesions [50] and both the proteomic and western blot
results from our study, suggest that this is reflected in our
cartilage explant model of early OA.
The abundance of cartilage ECM-associated proteins in the
top scoring entries highlights the specificity of this in vitro
model and the suitability of high throughput protein discovery
techniques for interrogating it. However, despite using a
targeted approach and an explant culture system, a small
number of non-matrix associated proteins were also identified
in the media of several samples, for example, vimentin, dynein
heavy chain, alpha enolase and the membrane bound sodium
hydrogen exchanger 2 (NHE2) (see Tables 2 and 3). There are a
number of possible explanations and interpretations for the
presence of these proteins. The most obvious explanation for
the presence of these non-ECM proteins is the high sensitivity
of the high-throughput approach for detecting proteins re-
leased from the cytoplasm following cell death; the detection of
these proteinsmay be attributable to a small number of dead or
dying chondrocytes. However, it is known that there are
frequently observed proteins in many proteomic experiments
regardless of species or tissue being studied, such as alpha
enolase and vimentin [51,52].
In addition to the cartilage ECM and chondrocyte-associated
proteins, the database search also detected some apparently
unlikely candidates for biomarkers of arthritis, for example
Bullous pemphigoid antigen or breast cancer type 2 protein
susceptibility homologue. However, it is highly likely that some
of these less abundant proteins with lower Mowse scores could
be proteins of interest in their own right or modifications of the
abundant proteins, which are relevant to OA. Ideal biomarkers
for OA are those that can indicate the very early stages of
disease before too much destruction has occurred [53]. There-
fore the bestmarkers of early OA are unlikely to be fragments or
degraded forms of major ECM proteins such as fibrillar
collagens [54]. Notably, we did not identify any fibrillar
collagens in this study. This adds weight to the argument that
incubating cartilage explants with IL-1β creates an environ-
ment that could mimic the early stages of OA. Although we
used a Mowse score of 40 as the cut-off point, it is possible that
proteins under the detection threshold could be potentially
useful biomarkers. For example, the protein arginine deiminase
type-4 (PADI4), which had a Mowse score of 39 (see Table 4), is
known to catalyse citrullination of arginine residues of
proteins. Citrullinated peptides can act as autoantigens
thereby increasing the risk of rheumatoid arthritis (RA) [55],
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synovial tissue from RA patients [56]. In addition, autoanti-
bodies against PADI4 are associated with increased RA
severity [57]. Although RA is an auto-immune disease, unlike
OA, the protein may have other functions and potential
involvement in OA. The presence of PADI4 in the supernatant
of the cartilage explants in this study may partly explain why
this enzyme could be a target of autoantibodies to citrullinated
proteins, in fact this antigen may not be as specific for
rheumatoid arthritis (RA) as previously suggested [58,59], the
enzyme may also be released in OA. PADI4 is one of the many
less abundant proteins identified in the model that may
be potential biomarkers. More studies with larger sample
numbersmay providemore information in this area. However,
greater potential lies in using methods that facilitate mining
below the abundant proteins in the secretome to allow robust
and clear detection of the lower abundance components. The
most obvious of these methods would be the depletion of the
major/high abundance proteins, which is commonly used
when studying biological fluids such as plasma and cerebro-
spinal fluid [60,61]. Another approach would be the use of
metabolic labelling during culture to allow the newly synthe-
sised proteins to be studied [62]. Adopting these approaches
will aid identification of these less abundant but potentially
more interesting proteins in terms of the molecular changes
accompanying early OA.
Proteomics has been used to study soluble extracts of
cartilage [24,63], chondrocyte whole cell lysates [64], synovial
fluid [65] and synovial fibroblasts [66], from both normal and
OA patients. More recently proteomics has been used to
characterise the extracellular space in tracheal in the human
aorta [67]. The cartilage explant model employed in our study
can reduce some of the confounding variables associated with
clinical samples such as individual variation, differing disease
aetiology and the stage of disease progression. In effect, using
the cartilage explant system provides a more homogenous
model with appropriate controls. In addition, explants can be
cultured in serum-free media, which address the technical
issue of contaminating serum albumins and other high
abundance proteins, which can prevent the identification of
the lower abundance proteins.
The advantage of a proteomic approach over a genomic
approach to studying potential disease indicators are that
gene expression levels do not necessarily correlate with
protein levels [68]. For example, CLU expression is increased
at the mRNA level in early OA cartilage and decreased in
advanced OA [69]. IL-1α-stimulated cartilage explants have
been shown to produce decreased levels of CLU compared to
untreated cartilage [25]. This could reflect the differences
between clinical cases and in vitro models of OA and the
various stimuli used to initiate cartilage degradation. Clearly,
further work is needed to look at levels of these proteins in the
synovial fluid and serum of clinical cases.5. Conclusions
This study refined an existing explant model of equine
articular cartilage and adapted it for subsequent high
throughput proteomic work. One of the key advantages ofthis cartilage explant model is that it is serum-free, so the
problem of contaminating serum proteins such as albumins
and immunoglobulins, which make up a large percentage of
serum, is eliminated using this approach. Another advantage
of this culture system is that the resident cells aremaintained
in their nativemicroenvironment overcoming the difficulties
and challenges associated with chondrocyte dedifferentia-
tion in proteomic studies that use primary cultured cells in
vitro [70]. Cross species peptidematching identified a number
of relevant proteins with well-established ECM functions in
cartilage including: cell–matrix and matrix–matrix interac-
tions (fibronectin, TSP-1, COMP, CHAD); matrix turnover
(MMP-1, MMP-3) and extracellular molecular chaperone
activity (CLU). Other proteomic studies using cartilage from
other species have identified similar panels of ECM proteins
[24,25,28]. Equine cartilage has not been examined previously
in this way and comparisons with the mouse, human and
bovine cartilage proteomes also substantiate data obtained in
those previous reports. These observations confirm and
complement previous studies in other species and are good
indicators for the usefulness of both the explant model
of cartilage inflammation and the high throughput metho-
dology used. It is important to point out that the basic biology
of articular cartilage and themolecularmechanisms involved
in its degradation in arthritis are essentially the same in all
mammalian species. Any reported differences observed
between different species could be due to different patho-
genic stimuli, the root aetiologies of the disease and the
biological reagents used in the experiments. Therefore, given
the many similarities that exist between equine and human
cartilage in the biological context, the results of this study
could be used for understanding disease processes in both
species.
Our novel approach justifies the application of high through-
put techniques in basic cartilage biology and OA research.
Furthermore, this strategymay identify clinically useful secreted
biomarkers for identifying structural and biochemical changes
in early stages of OA. The explant culture system employed also
facilitated a surprisingly rapid and ‘clean’ analysis of secreted
proteins in our in vitromodel of cartilage inflammation. Thiswas
an important and novel element of this study. Furthermore, the
horse is a large animal model that may serve as a surrogate for
human OA and may eventually lead to the discovery of
candidate biomarkers. Future studies will exploit this serum-
free model to investigate the effects of other pro-inflammatory
cytokines and pathophysiologically relevant catabolic stimuli
such as mechanical injury [71].Competing interests
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